TrialActa ophthalmologica2022

Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.

Andreas Stahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.